RELEASE OF MEDIATORS OF ANAPHYLAXIS: INHIBITION OF PROSTAGLANDIN SYNTHESIS AND THE MODIFICATION OF RELEASE OF SLOW REACTING SUBSTANCE OF ANAPHYLAXIS AND HISTAMINE-Reference-Cited by-同舟云学术

RELEASE OF MEDIATORS OF ANAPHYLAXIS: INHIBITION OF PROSTAGLANDIN SYNTHESIS AND THE MODIFICATION OF RELEASE OF SLOW REACTING SUBSTANCE OF ANAPHYLAXIS AND HISTAMINE

Published:1978-01 Issue:1 Volume:62 Page:61-66
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:

Author:

ENGINEER DINAZ M.,NIEDERHAUSER U.,PIPER PRISCILLA J.,SIROIS P.

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1476-5381.1978.tb07006.x/fullpdf

Reference25 articles.

1. Selective inhibitor of slow reacting substance of anaphylaxis;Augstein;Nature, New Biol.,1973

2. The relationship between prostaglandin-like substances and SRS-A released from immunologically challenged lungs;Boot;Br. J. Pharmac.,1977

3. The pharmacology of prostaglandin-like substances released from guinea-pig lungs during anaphylaxis;Boot;Prostaglandins,1977

4. Slow reacting substance and related compounds;Brocklehurst;Prog. Allergy,1962

5. Modulation of the formation and release of bovine SRS-A in vitro by several anti-anaphylactic drugs;Burka;Int. Archs Allergy appl. Immun.,1975

Cited by 201 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostaglandin D2 inhibits mediator release and antigen induced bronchoconstriction in the Guinea pig trachea by activation of DP1 receptors;European Journal of Pharmacology;2021-09

2. Leukotrienes: One step in our understanding of asthma;Respiratory Investigation;2019-03

3. Nonsteroidal anti-inflammatory drugs in Parkinson’s disease: possible involvement of quinone formation;Expert Review of Neurotherapeutics;2006-09

4. Involvement of enhanced neurokinin NK3 receptor expression in the severe asthma guinea pig model;European Journal of Pharmacology;2004-09

5. Neuroprotective Effects of Nonsteroidal Anti-inflammatory Drugs on Neurodegenerative Diseases;Current Pharmaceutical Design;2004-02-01